Microbot Medical (MBOT) said Wednesday that robotic endovascular procedures using its Liberty robotic system are feasible and significantly minimize radiation exposure, based on data from a study.
According to the study, successful robotic navigation was achieved in 20 cases, meeting its primary endpoint, the company said.
The study also resulted in a mean 92% reduction in radiation exposure.
The company said it may now move to building commercial capabilities and launch preparation, according to its President and CEO Harel Gadot.
Microbot Medical shares were up over 33% in premarket trading Wednesday.
Price: 1.86, Change: +0.47, Percent Change: +33.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.